Improved Diagnosis of Alzheimer's Disease Using the Synchronous Neural Interaction™ Test

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-04-30

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to test the hypothesis that the Synchronous Neural Interaction™ Test is useful for diagnosing Probable Alzheimer's Disease according to standard criteria. Subjects diagnosed with Alzheimer's Disease as well as age-matched normal control subjects will be evaluated for symptoms of Alzheimer's Disease and those meeting inclusion criteria will undergo a brief, non-invasive scan of brain function using a magnetoencephalography (MEG). The scan itself lasts 1 minute while the subject is asked to stare at a dot projected in front of them on a video screen. Orasi Medical believes that patterns of brain activity measured at rest are indicative of Alzheimer's Disease pathology.

The protocol is amended to add a follow-up assessment for previously enrolled and completed subjects who agree to participate in the follow-up assessment approximately 9 - 15 months after initial study enrollment. Subjects who agree to participate in the follow-up assessment will undergo the same standardized tests and MEG scan procedure as completed in the initial study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease

NCT00933608

Alzheimer's Disease

COMPLETED PHASE4

Minocycline in Patients With Alzheimer's Disease

NCT01463384

Mild Cognitive Impairment Alzheimer's Disease

COMPLETED PHASE2

Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease)

NCT00334906

Alzheimer's Disease

COMPLETED PHASE4

Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers

NCT00785759

Alzheimer's Disease Amnestic Mild Cognitive Impairment

COMPLETED PHASE2

Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease

NCT00857649

Alzheimer's Disease

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Patients diagnosed with Alzheimer's Disease

No interventions assigned to this group

2

Aged-matched normal controls

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is between 18 and 90 years of age
3. Have one of the following clinical diagnoses or conditions:

* Probable AD according to the NINCDS-ADRDA criteria
* Possible AD according to the NINCDS-ADRDA criteria
* Prodromal AD according to criteria described by Dubois \& Albert (2004)
* Normal control subject

Subjects who completed Protocol ADG 08-01 will be contacted and invited to participate in the follow-up assessment.

Exclusion Criteria

1. Have a significant non-AD neurological condition including Parkinson's Disease, Vascular Dementia, Lewy Body Dementia or Frontal Temporal Dementia, human immunodeficiency virus, multiple sclerosis, epilepsy, or severe traumatic brain injury.
2. Have dementia due to multiple etiologies (e.g. mixed dementia)
3. Show the presence of prominent disturbances in gait thought to be associated with Parkinsonism.
4. Show prominent changes in personality or social conduct prior to the onset of prominent cognitive dysfunction
5. Have a Modified Hachinski Ischemia Scale score of greater than 4
6. Have a history of primary psychotic disorder (e.g schizophrenia, schizoaffective disorder, delusional disorder) or bipolar disorder
7. Have a lifetime or current history of alcohol or substance abuse/dependence
8. Have had an MRI two weeks prior to completing the MEG scan
9. Have metal braces or pacemaker that may interfere with the MEG scan
10. Are unable to complete the MEG scan procedure

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes